Editorial: Spotlight on the Relationship Between Sepsis and Infection: From Mechanisms to Therapy.
作者信息
Russo Alessandro, Paterson David L, Bassetti Matteo
机构信息
Infectious and Tropical Disease Unit, Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia.
出版信息
Front Med (Lausanne). 2021 Aug 2;8:716215. doi: 10.3389/fmed.2021.716215. eCollection 2021.
Abstract
摘要
相似文献
1
Editorial: Spotlight on the Relationship Between Sepsis and Infection: From Mechanisms to Therapy.社论：聚焦脓毒症与感染之间的关系：从机制到治疗
Front Med (Lausanne). 2021 Aug 2;8:716215. doi: 10.3389/fmed.2021.716215. eCollection 2021.
3
Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock.使用治疗所需人数来评估恰当的抗菌治疗，以此作为严重脓毒症和脓毒性休克预后的一个决定因素。
Crit Care Med. 2014 Nov;42(11):2342-9. doi: 10.1097/CCM.0000000000000516.
4
Optimizing antimicrobial therapy of sepsis and septic shock: focus on antibiotic combination therapy.优化脓毒症和脓毒性休克的抗菌治疗：聚焦抗生素联合治疗。
Semin Respir Crit Care Med. 2015 Feb;36(1):154-66. doi: 10.1055/s-0034-1398742. Epub 2015 Feb 2.
5
Sepsis Care Pathway 2019.2019年脓毒症护理路径
Qatar Med J. 2019 Nov 7;2019(2):4. doi: 10.5339/qmj.2019.qccc.4. eCollection 2019.
6
Impact of appropriate antimicrobial therapy for patients with severe sepsis and septic shock--a quality improvement study.适当的抗菌治疗对严重脓毒症和脓毒性休克患者的影响——一项质量改进研究。
PLoS One. 2014 Nov 6;9(11):e104475. doi: 10.1371/journal.pone.0104475. eCollection 2014.
7
Antimicrobial management of sepsis and septic shock.脓毒症和脓毒性休克的抗菌治疗
Clin Chest Med. 2008 Dec;29(4):677-87, ix. doi: 10.1016/j.ccm.2008.06.004.
8
Optimizing antimicrobial therapy in sepsis and septic shock.优化脓毒症和脓毒性休克的抗菌治疗。
Crit Care Clin. 2009 Oct;25(4):733-51, viii. doi: 10.1016/j.ccc.2009.08.004.
9
De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock.成人脓毒症、严重脓毒症或脓毒性休克抗菌治疗的降阶梯治疗
Cochrane Database Syst Rev. 2010 Dec 8(12):CD007934. doi: 10.1002/14651858.CD007934.pub2.
10
A Cohort Study of the Impact of Carbapenem-Resistant Infections on Mortality of Patients Presenting with Sepsis.一项关于碳青霉烯类耐药感染对脓毒症患者死亡率影响的队列研究。
mSphere. 2019 Apr 10;4(2):e00052-19. doi: 10.1128/mSphere.00052-19.
引用本文的文献
1
Lights and Shadows of Sepsis Management: Challenges and Future Perspectives.脓毒症管理的光明与黑暗：挑战与未来展望。
Int J Mol Sci. 2023 May 29;24(11):9426. doi: 10.3390/ijms24119426.
本文引用的文献
1
Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria.近期用于治疗产 ESBL 细菌所致严重感染的药物分子。
Expert Rev Anti Infect Ther. 2021 Aug;19(8):983-991. doi: 10.1080/14787210.2021.1874918. Epub 2021 Feb 17.
2
Spotlight on New Antibiotics for the Treatment of Pneumonia.聚焦用于治疗肺炎的新型抗生素
Clin Med Insights Circ Respir Pulm Med. 2020 Dec 20;14:1179548420982786. doi: 10.1177/1179548420982786. eCollection 2020.
3
Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study.含磷霉素方案治疗多重耐药鲍曼不动杆菌所致重症肺炎的疗效：一项前瞻性观察研究。
Infect Dis Ther. 2021 Mar;10(1):187-200. doi: 10.1007/s40121-020-00357-8. Epub 2020 Oct 17.
4
Inhaled Liposomal Antimicrobial Delivery in Lung Infections.吸入型脂质体抗菌药物递药系统治疗肺部感染。
Drugs. 2020 Sep;80(13):1309-1318. doi: 10.1007/s40265-020-01359-z.
5
Emerging drugs for treating methicillin-resistant .治疗耐甲氧西林金黄色葡萄球菌的新兴药物
Expert Opin Emerg Drugs. 2019 Sep;24(3):191-204. doi: 10.1080/14728214.2019.1677607.
6
Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study.由耐碳青霉烯鲍曼不动杆菌引起的血流感染：一项多中心研究的临床特征、治疗和结局。
J Infect. 2019 Aug;79(2):130-138. doi: 10.1016/j.jinf.2019.05.017. Epub 2019 May 28.
7
New Antibiotics for Pneumonia.肺炎新抗生素。
Clin Chest Med. 2018 Dec;39(4):853-869. doi: 10.1016/j.ccm.2018.08.007.
8
Rational approach in the management of Pseudomonas aeruginosa infections.合理的方法来管理铜绿假单胞菌感染。
Curr Opin Infect Dis. 2018 Dec;31(6):578-586. doi: 10.1097/QCO.0000000000000505.
9
Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control.耐多药肺炎克雷伯菌：治疗、预防和感染控制面临的挑战。
Expert Rev Anti Infect Ther. 2018 Oct;16(10):749-761. doi: 10.1080/14787210.2018.1522249. Epub 2018 Sep 19.
10
Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria.重症监护病房获得性多重耐药/广泛耐药/泛耐药菌肺炎的风险分层与治疗。
Curr Opin Crit Care. 2018 Oct;24(5):385-393. doi: 10.1097/MCC.0000000000000534.
Zotero 插件